Targeted Protein Degradation: "The Gold Rush is On!"

Author(s): Daria Kotlarek, Agata Pawlik, Maria Sagan, Marta Sowała, Alina Zawiślak-Architek, Michał J. Walczak*.

Journal Name: Technology Transfer and Entrepreneurship

Volume 7 , Issue 1 , 2020

Become EABM
Become Reviewer


Targeted Protein Degradation (TPD) is an emerging new modality of drug discovery that offers unprecedented therapeutic benefits over traditional protein inhibition. Most importantly, TPD unlocks the untapped pool of the proteome that to date has been considered undruggable. Captor Therapeutics (Captor) is the fourth global, and first European, company that develops small molecule drug candidates based on the principles of targeted protein degradation. Captor is located in Basel, Switzerland and Wroclaw, Poland and exploits the best opportunities of the two sites – experience and non-dilutive European grants, and talent pool, respectively. Through over $38 M of funding, Captor has been active in three areas of TPD: molecular glues, bi-specific degraders and direct degraders, ObteronsTM.

Keywords: Targeted protein degradation, PROTAC, degraders, proteasome, cancer, oncology.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [4 - 16]
Pages: 13
DOI: 10.2174/2213809907666200130111436
Price: $25

Article Metrics

PDF: 11